Furthermore, recent progress in basic and translational research has improved treatment options for lymphoma, including FDA-approved crizotinib for ALK-positive ALCL and Brentuximab Vedotin for CD30-positive T-cell lymphoma [4, 5]. This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.